Gene tests aim to Fine-Tune Kids' cancer drug, reduce dangerous side effects
NCT ID NCT07462299
Summary
This study is testing a new approach to dosing a common leukemia drug called 6-MP for children. Researchers will use genetic test results to personalize the starting dose for each child during long-term maintenance therapy. The goal is to see if this gene-guided dosing can reduce severe drops in white blood cells and serious infections compared to standard dosing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.